Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Carnival CEO Comments on the Current State of the Cruise Industry

Carnival Corp. Chief Executive Officer Arnold Donald expressed optimism for recovery in the cruise industry, citing pent-up demand from regular cruisers. Donald spoke with Bloomberg’s Ed Hammond about these topics and more. Watch or read the transcript below. — Donald: We [Carnival] have a nice liquidity runway, we’re at the point where we still have…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share
Carnival CEO Comments on the Current State of the Cruise Industry

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

Carnival Corp. Chief Executive Officer Arnold Donald expressed optimism for recovery in the cruise industry, citing pent-up demand from regular cruisers. Donald spoke with Bloomberg’s Ed Hammond about these topics and more. Watch or read the transcript below.

Donald: We [Carnival] have a nice liquidity runway, we’re at the point where we still have additional debt, we could secure if we needed it, and obviously, we will be opportunistic with regards to the balance sheet overall and in terms of equity. And so on. But at this point, we have the liquidity.

We need, you know, for to take us well into next year. And so with zero revenue. And obviously, we’re hoping to have some revenue this year and the beginning, it was a tough time.

You know, some of the debt we raise were at rates, you know, that we never would have even considered in the past. Then even more recent ones are at rates where we’re happy about them now. But, you know, two years ago, we wouldn’t have been happy with those rates.

So it is what it is. But, you know, we’ll adapt. And we have a great resilient business, a great resilient industry.

We will be able to generate lots of cash. And over time, we’ll get back to the solid credit rating that we had prior to the pandemic.

Host: I’m interested in that resilience that you mentioned on, because if I look at this industry, I mean, look, every industry has suffered through COVID. But I think when I think about the cruise industry, there have been some real and very visceral horror stories that have gone on over the last year. I understand you have a sticky customer base, but how do you pitch this as a model to new potential cruises?

Donald: As we look ahead, we have over eight million repeat cruises in our world. And of carnival and our nine world brands. And there’s pent up demand, a cruise on average once every two years.

And so there’s a whole year of repeat cruises basically that haven’t been able to cruise. And so we have plenty of pent up demand. Additionally, we reduced the size of the fleet because obviously, we had ships that were less efficient, and it didn’t make sense when they weren’t generating revenue to continue to invest in those ships.

That’s one way we got our burn rate down. And so we plan to exit 19 ships. So that takes our capacity down when we do come back.

Furthermore, it’s going to be a staggered return. All the destinations aren’t going to open up at once. Different destinations will open at different times.

And so there will be plenty of pent up demand, as is evidenced by the bookings already. As you look at late 2021 and first half, second half of 2022, where the bookings are stronger than they were even prior to COVID on the same basis.

Host: But also, if the cruise from what I understand, this is right, if the cruise of the near future is sort of more people, you know, on these boats in sort of isolation from one another and lose something of its essence, I mean, isn’t the whole allure of going on a cruise that you get these you know, you get to jostle and mingle with strangers, you have this sort of conviviality by the waves. If you don’t have that, then do people really want to go cruising?

Donald: Look, first of all, you’re absolutely right that travel and cruising in particular is about people connecting with other people. What people remember are other people on the cruise ships. The ships are fabulous. We have lots of features, but it’s all about the human spirit and human exchange. And people learn what they have in common. And then they learn to celebrate the differences rather than fear them. And that’s whether it’s through the guests to guests, or guests to the locals of the various destinations that they visit. So you’re absolutely right about that. Having said that, we are ready to resume cruising in Italy and with our Constitution and in Germany on a very limited basis. But our net promoter scores and basically our guest satisfaction scores went through the roof. People love the experience.

*Bloomberg contributed to this content

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Interchangeable biosimilars are getting approved faster, and Wezlana shows why

Interchangeable biosimilars are getting approved faster, and Wezlana shows why

The FDA approved Wezlana (ustekinumab-auub) as a biosimilar to and interchangeable with Stelara for multiple inflammatory diseases, which means it may be substituted without consulting the prescriber, subject to state pharmacy laws. A Springer analysis reported 26 interchangeable biosimilars approved since 2020 and said average approval timelines decreased from 798 days for applications dated in 2020 to 364 days for applications dated in 2024. The operational pressure shifts to formulary, payer, and specialty pharmacy workflow design.

  • 01Interchangeability is becoming the default ask, not an afterthought: Springer found 17 of 26 approvals pursued interchangeability concurrently, which changes how buyers should time contracting and conversions.
  • 02Springer reported average approval timelines decreased from 798 days for applications dated in 2020 to 364 days for applications dated in 2024, which can compress planning windows for monitoring and implementation.
  • 03A new interchangeable ustekinumab option means the hard work is no longer clinical, it is operational: NDC mapping, EMR preference lists, substitution rules by state, and patient communications decide whether savings show up.

Sep 8, 2026

AAO-HNSF hearing loss guideline moves audiograms and amplification into primary care

AAO-HNSF’s new age-related hearing loss guideline calls for screening adults starting at age 50 and escalating to otoscopy, audiogram, and appropriately fit amplification. It shifts hearing loss from “patient complaint” to a routine primary-care workflow. The pressure shows up in audiology capacity, referral design, and documentation standards.

  • 01Screening at age 50 becomes a repeatable workflow, so capacity planning shifts from episodic ENT referrals to steady primary-care volume, especially where annual wellness visits are a dominant access point.
  • 02The guideline’s escalation sequence, screen, otoscopy, audiogram, amplification, then cochlear implant candidacy evaluation, creates a measurable funnel that health systems can instrument in the EHR and manage like any other pathway.
  • 03Asymmetric loss remains a separate trigger for MRI in many settings, and 2026 pre-proof work using NHANES and SEER highlights why imaging criteria choices can swing scan volume, a budgeting and radiology access issue, not a clinical footnote.

Sep 7, 2026

ADHA shifts My Health Record to multi-supplier ops as Accenture signs new 3-year contract

ADHA shifts My Health Record to multi-supplier ops as Accenture signs new 3-year contract

Accenture will keep supporting Australia’s My Health Record under a new three-year contract. ADHA is moving the platform to a multi-supplier operating model. The shift raises questions about shared integration discipline, tooling, and accountability when changes hit production.

  • 01Multi-supplier delivery is spreading across national-scale health platforms, as ADHA's My Health Record shift shows, moving risk from vendor selection to integration, runbooks, and accountability.
  • 02GenAI model upgrades are arriving with healthcare-specific claims, but the procurement work moves to evidence, safety controls, and monitoring once models sit inside clinical workflows.
  • 03Embedded AI expands the cyber asset inventory problem: if teams cannot discover the AI components across endpoints and devices, they cannot reliably secure or audit them.

Sep 7, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512